Quality of life and drug compliance: their interrelationship in rheumatic patients

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11150%2F15%3A10312371" target="_blank" >RIV/00216208:11150/15:10312371 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11160/15:10312371 RIV/00179906:_____/15:10312371

Výsledek na webu

<a href="http://onlinelibrary.wiley.com/doi/10.1111/jep.12399/full" target="_blank" >http://onlinelibrary.wiley.com/doi/10.1111/jep.12399/full</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/jep.12399" target="_blank" >10.1111/jep.12399</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Quality of life and drug compliance: their interrelationship in rheumatic patients

Popis výsledku v původním jazyce

A cross-sectional study was conducted and patients >= 18 years of age with rheumatoid arthritis (RA), spondyloarthritis (SA), juvenile idiopathic arthritis (JIA) and systemic scleroderma (SSc) were recruited. Data were collected by questionnaires including the Short Form 36 version 2, Compliance Questionnaire Rheumatology (CQR), Health Assessment Questionnaire and by a general questionnaire that focused on demographic characteristics. The questionnaires were completed by 289 patients. Of the respondents, 61.6% (178) were treated for RA, 16.3% (47) for SA, 14.2% (41) for SSc and 8% (23) for JIA. The median of CQR score ranged from 66.7 (JIA) to 82.5 (RA), with 51.6% of patients reaching a score <80. QoL was decreased mainly in the physical component, with the lowest rate for patients with SSc. Higher compliance was observed in patients with decreased QoL (physical component), nevertheless, statistical significance of the relationship was reached only in JIA and SA patients.

Název v anglickém jazyce

Quality of life and drug compliance: their interrelationship in rheumatic patients

Popis výsledku anglicky

A cross-sectional study was conducted and patients >= 18 years of age with rheumatoid arthritis (RA), spondyloarthritis (SA), juvenile idiopathic arthritis (JIA) and systemic scleroderma (SSc) were recruited. Data were collected by questionnaires including the Short Form 36 version 2, Compliance Questionnaire Rheumatology (CQR), Health Assessment Questionnaire and by a general questionnaire that focused on demographic characteristics. The questionnaires were completed by 289 patients. Of the respondents, 61.6% (178) were treated for RA, 16.3% (47) for SA, 14.2% (41) for SSc and 8% (23) for JIA. The median of CQR score ranged from 66.7 (JIA) to 82.5 (RA), with 51.6% of patients reaching a score <80. QoL was decreased mainly in the physical component, with the lowest rate for patients with SSc. Higher compliance was observed in patients with decreased QoL (physical component), nevertheless, statistical significance of the relationship was reached only in JIA and SA patients.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FR - Farmakologie a lékárnická chemie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Evaluation in Clinical Practice

ISSN

1356-1294

e-ISSN

—

Svazek periodika

21

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

6

Strana od-do

919-924

Kód UT WoS článku

000363881200020

EID výsledku v databázi Scopus

2-s2.0-84944169209